Evidence map›Paper›PMID 39000194›Full record

ArticleInternational journal of molecular sciences2024

A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer.

Aditi A Shirke, Ethan Walker, Sriprada Chavali, Gopalakrishnan Ramamurthy, Lifang Zhang, Abhiram Panigrahi, James P Basilion, Xinning Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Special Issue "Molecular Advances in Oncological Photodynamic Therapy".International journal of molecular sciences · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aditi A ShirkeDepartment of Biomedical Engineering, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0002-5601-3308
Ethan WalkerDepartment of Biomedical Engineering, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0002-5132-8191
Sriprada ChavaliDepartment of Biochemistry, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.
Gopalakrishnan RamamurthyDepartment of Radiology, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0001-6813-429X
Lifang ZhangDepartment of Radiology, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.
Abhiram PanigrahiDepartment of Radiology, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0001-8885-4390
James P BasilionDepartment of Biomedical Engineering, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0002-8659-3307
Xinning WangDepartment of Biomedical Engineering, Case Western Reserve University, 11100 Euclid Ave, Cleveland, OH 44106, USA.ORCID 0000-0001-7729-0534

Funding

NIH HHS 1R01CA255925-01A
6 · The paper itself

Abstract

Prostate cancer is the most prevalent cancer among men in the United States and is a leading cause of cancer-related death. Prostate specific membrane antigen (PSMA) has been established as a biomarker for prostate cancer diagnosis and treatment. This study aimed to develop a novel theranostic agent, PSMA-1-MMAE-Pc413, which integrates a PSMA-targeting ligand, the photosensitizer Pc413, and the microtubular inhibitor monomethyl auristatin E (MMAE) for synergistic therapeutic efficacy. In vitro uptake studies revealed that PSMA-1-MMAE-Pc413 demonstrated selective and specific uptake in PSMA-positive PC3pip cells but not in PSMA-negative PC3flu cells, with the uptake in PC3pip cells being approximately three times higher. In vitro cytotoxicity assays showed that, when exposed to light, PSMA-1-MMAE-Pc413 had a synergistic effect, leading to significantly greater cytotoxicity in PSMA-positive cells (IC

Indexed as

PhotochemotherapyPhotosensitizing AgentsProstatic NeoplasmsAnimalsAntigens, SurfaceAntineoplastic AgentsCell Line, TumorDrug SynergismGlutamate Carboxypeptidase IIHumansMaleMiceOligopeptidesXenograft Model Antitumor AssaysAntigens, SurfaceAntineoplastic AgentsFOLH1 protein, humanGlutamate Carboxypeptidase IImonomethyl auristatin EOligopeptidesPhotosensitizing Agentschemotherapycombination treatmentphotodynamic therapyprostate cancerPSMA

Identifiers

PMID39000194
PMCPMC11241360

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.